

Under the auspices of:

Ministero della Salute



Istituto
Superiore
di Sanità



THIRD WORKSHOP ON DRUG PRICING

SCIENTIFIC BOARD:

Pier Luigi Canonico
Armando Genazzani
Claudio Jommi

MILAN

MAY 4th | 5th, 2017

Sala Colonne, Palazzo Giureconsulti
Piazza dei Mercanti 2

Under the auspices of:

Ministero della Salute



Istituto
Superiore
di Sanità





OBJECTIVE

Achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing on horizon scanning, access to innovation, current and future role of insurances and private providers

SESSION

I

**HORIZON SCANNING:
EFFECTS OF THE PIPELINES AND PATENT EXPIRY**

II

**ECONOMIC SUSTAINABILITY OF CARE MODELS:
ADVANTAGES AND DISADVANTAGES OF PRIVATIZATIONS**

III

**INNOVATION:
HOW TO MEASURE AND REIMBURSE INNOVATION**

IV

**ACCESS TO INNOVATION:
A COMPARISON AMONG COUNTRIES**

14.00 Registration

14.15 Introduction
Pier Luigi Canonico, Armando Genazzani, Claudio Jommi

14.30 *Lecture*
Perspectives on pharma expenditure funding and policies to incentivate companies
Paolo Bonaretti

SESSION I

HORIZON SCANNING: EFFECTS OF THE PIPELINES AND PATENT EXPIRY

Chairperson: Claudio Jommi

15.00 Horizon Scanning and forecast of expenses: methods and prospects of use
Claudio Jommi

15.40 The experience of the Italian Horizon Scanning Project
Roberta Joppi

16.00 Models for drug sales forecasting
Cinzia Mortarino

16.20 Discussion

16.45 *Break*

SESSION II

ECONOMIC SUSTAINABILITY OF CARE MODELS: ADVANTAGES AND DISADVANTAGES OF PRIVATIZATIONS

Chairperson: Claudio Jommi

17.00 Future trend and expectations for funding and expenditure of the National Health Service
Marina Cavazza

17.20 ROUNDTABLE | Sustainability of care models

- Insurances
Giacomino Vallar
- Mutual aid
Massimo Piermattei

18.00 Discussion

18.30 Conclusion
Pier Luigi Canonico, Armando Genazzani, Claudio Jommi

09.00 Introduction
Pier Luigi Canonico, Armando Genazzani, Claudio Jommi

09.10 *Lecture*
Innovation and sustainability: AIFA vision
Mario Melazzini

SESSION III

INNOVATION: HOW TO MEASURE AND REIMBURSE INNOVATION

Chairperson: Armando Genazzani

09.40 Pricing and Reimbursement in Italy. Numbers and challenges
Elena Paola Lanati

10.00 Criteria for the assessment of innovation
Patrizia Popoli

10.20 ROUNDTABLE | How to measure innovation
Maurizio de Cicco
Annarita Meneguz
Riccardo Palmisano
Francesca Patarnello
Patrizia Popoli
Giuseppe Toffoli

11.15 *Break*

SESSION IV

ACCESS TO INNOVATION: A COMPARISON AMONG COUNTRIES

Chairperson: Pier Luigi Canonico

11.30 Access and funding of oncology drugs in France
Carole Omnès

11.50 Decentralised HTA process: the case of Spain
Oriol Solà-Morales

12.10 Biologics as a treatment class and its challenges
Hayden Holmes

12.30 Discussion

13.00 Market Access Award prize-giving ceremony
Pier Luigi Canonico, Armando Genazzani, Claudio Jommi, Elena Paola Lanati

13.30 Conclusion
Pier Luigi Canonico, Armando Genazzani, Claudio Jommi

PIER LUIGI CANONICO

PROFESSOR OF PHARMACOLOGY,
UNIVERSITA' DEL PIEMONTE ORIENTALE

Pier Luigi Canonico, MD and Specialist in Endocrinology and Metabolic Diseases, became Full Professor of Pharmacology at the Faculty of Medicine and Surgery at the University of Pavia in 1990; in 1999 he moved as Professor of Pharmacology and Pharmacotherapy to the Faculty of Pharmacy of the Università del Piemonte in Novara. He was Chairman of the Department of Chemical, Nutritional, Pharmaceutical and Pharmacological Sciences (DISCAFF) from 2000 to 2008, Vice Dean of the Faculty from 2008 to 2009 and Dean from 2009 to 2011, Member of the Board of Directors of the University (2000-2001); actually he is also Member of the Senato Accademico (since 2002). Since 2012 Prof. Canonico is Chairman and Dean of the Department of Pharmaceutical Sciences. He was the CEIMS Director from 2012 to 2013, and CEIMS Member of the Board since 2014.

Professor Canonico is member of several national and international scientific societies: among these, the Italian Society of Pharmacology (Councilor for 10 years and President from 2011 to 2013) and the Italian Society of Neuropsychopharmacology (member of the Council since 2006). Among his extra-academic assignments, Member of the Commissione Unica del Farmaco (CUF) (Commission for Drug Approval and Reimbursement) of the Italian Ministry of Health (2001-2003), Vice-president of the Ethical Committee of the Institute for Neurological Research Casimiro Mondino (2006-2010), Member of the Scientific Group for Innovative Pharmacology (Biological Drugs) of the Presidenza del Consiglio dei Ministri (2008-2010), Member of the Regional Committee for the Organization of the Regional Network for Pain Therapy (Regione Piemonte). He is a Member of the Scientific Board of CeSBio and ISPOR Italy Rome Chapter Director.

Prof. Canonico research includes several areas in the field of neuropsychopharmacology, neuroendocrinology, neurobiology, cancer therapy, pharmacogenetics/genomics and issues concerning biotechnology drugs. He is author of over 200 publications on international journals.

ARMANDO GENAZZANI



PROFESSOR OF PHARMACOLOGY,
UNIVERSITA' DEL PIEMONTE ORIENTALE

Graduated in Medicine and Surgery at the University of Catania in 1992.

He then spent several years in Oxford, Zurich and Cambridge, working mainly on Ca²⁺-signalling and signal transduction in health and disease. In Cambridge, he was appointed University Lecturer at the Department of Pharmacology and Official Fellow of Clare Hall.

Since 2003 he is Professor of Pharmacology at the Piemonte Orientale University, and was appointed full professor in 2011. His research still focuses on the role of signal transduction in health and disease, including Alzheimer's disease and oncological diseases, as well as on pharmacogenetics. He is author of over 130 publications on international journals.

He also developed an interest in scientific, regulatory and market access-related issues in the pharmaceutical sector. In this area, along with Professor Canonico and Professor Jommi, organizes a Master in "Regulatory Disciplines and Market Access" at the Department of Pharmaceutical Sciences in Novara. He is an expert since 2013 of the WHO "International non-proprietary names committee" and has been vice-chair for biologicals at the 62nd consultation. He is a member of the "Commissione Tecnico-Scientifica" of the Italian Medicines Agency since 2005. From 2013 to 2015 he was an elected member of the board of the Italian Society of Pharmacology.

CLAUDIO JOMMI



ASSOCIATE PROFESSOR OF MANAGEMENT AT THE DEPARTMENT OF
PHARMACEUTICAL SCIENCES, UNIVERSITA' DEL PIEMONTE ORIENTALE

Claudio Jommi is Associate Professor of Management at the Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara. He is also Director of the Pharmaceutical Observatory at Cergas (Centre for Research on Health and Social Care Management), Bocconi University, and Professor at Bocconi School of Management, Public Management and Policy Department, where he coordinates the Specialisation in Pharmaceuticals and Medical Technologies, Master in International Health Management Economics and Policy (Mihmep). He is President of the Italian Health Economics Association.

He has been Visiting Professor at Essec Business School, Cergy (Paris), at the Herivan K. Haub School of Business, St Joseph University, Philadelphia (USA), at the Andrija School of Public Health, Zagreb and the University of Claude Bernard Lyon 1 (European Market Access University Diploma). His research activity is focused on Pharmaceutical Economics, Policy and Management, Health Technology Assessment and Decision Making in Health Care.

He has published in many international and national journals, including Drug Design Development and Therapy, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics, PLOS Neglected Diseases, Public Money and Management.

PAOLO BONARETTI



ASTER GENERAL MANAGER

From 1992 to now, General Director of ASTER S. Cons. p. A. (the Consortium including Emilia-Romagna regional administration, the Universities located in the regional territory, CNR, ENEA, working in collaboration with the industrial associations).

From September 2015 to now President of E35 Foundation, the Foundation for the International Planning of the Chamber of Commerce of Reggio Emilia, Italy

Since May 2013 Councillor for the Industrial Policies of the Cabinet of the Ministry of Economic Development, and from 2008 to 2010 Member of the Panel of Experts of Industrial Policy of the Ministry.

Since 2015 Coordinator of the Pharmaceutical Working Table of the Ministry of Economic Development, and of its related Working Groups.

Coordinator of the S3 - Smart Specialization Strategy "Food, Health and Quality of Life" Working Group of the Italian Premiership.

Since January 2014 Deputy President of Ecolabel Ecoaudit Committee of the Ministry of Environment and President of the EMAS Section.

Since February 2015 to now Referent for Enterprise Europe Network Italy for relations with national Institutions. From 2011 to 2014, official spokesman of SAG - Steering Advisory Group (Italy) of Enterprise Europe Network, and since the end of 2009 appointed the Italian representative for the year 2010 within the SAG of the Enterprise Europe Network.


In December 2011, he was appointed member of the Scientific Committee of Bologna Metropolitan Strategic Plan and Manager of the Innovation and Development Board.

From 2004 to now President of SPINNER - consortium for the promotion of innovation and research Executive roles in CRS4 srl, I TECH OFF, the Incubator and Consortium for a new hi-tech companies' entrepreneurs, and DEMOCENTER.

Expert auditor of the European Commission - DG Research, and tutor of the Ministry of University and Research for the National Operational Programme of Scientific and Technological Research.

From 2008 to 2013 Member of the Advisory Board of the TTVenture - Fondamenta SGR fund, the first private equity fund in Italy.

MARIANNA CAVAZZA



CONTRACTED RESEARCHER, CERGAS - BOCCONI UNIVERSITY
CENTRE OF RESEARCH ON HEALTH AND SOCIAL CARE MANAGEMENT

Marianna Cavazza is contracted researcher at Cergas - Bocconi University and she is a member of the Observatory on Private Consumption in Healthcare Sector (Osservatorio sui Consumi Privati in Sanità) of SDA Bocconi.

Previously, she had experience in private and public research centres.

MAURIZIO DE CICCO



VICE PRESIDENT OF FARMINDUSTRIA,
PRESIDENT, MANAGING DIRECTOR & GENERAL MANAGER, ROCHE ITALY

Graduated cum laude in biologic sciences at Naples University, PhD cum laude in Marine Biology (Aquarium Institute A. Dohrn, Naples). He obtained several master degrees at SDA Bocconi University in Milan, INSEAD in Fontainebleau, London Business School.

In 1982 he started his career in Roche S.p.A., covering roles of increasing responsibility: from Operations Director to Business Pharma Director, with the management of marketing, sales and medical divisions, as well as all functions of support to the organization. He is president and CEO of Roche Italia since 2005.

He is Vice President of Farmindustria accountable for leading innovation and Agenda talks with the Italian Medicines Agency, Chairman of the Italian European Pharmaceutical Group (GEF) within Farmindustria, Member of the Board of Directors of Roche Diagnostics Italy and Member of the Advisory Board of the Swiss Chamber of Commerce in Italy.

HAYDEN HOLMES




SENIOR RESEARCH CONSULTANT,
YORK HEALTH ECONOMICS CONSORTIUM

Hayden Holmes has a Post Graduate Diploma in Public Health Medicine from the University of Otago in New Zealand. Hayden is experienced in developing economic models, research and critical appraisal. Prior to joining YHEC, Hayden lived and worked in New Zealand, working in health economics and health policy. Hayden has spent six years working for PHARMAC, which is the government agency responsible for making decisions on which medicines, vaccines, hospital medical devices, cancer and haemophilia treatments are publicly funded in New Zealand. Hayden spent two years as a policy advisor on a medical devices project establishing the policies and processes for Pharmac to manage the procurement of all medical devices into publically funded hospitals in New Zealand. Hayden worked as a health economist at Pharmac and was heavily involved in the prioritisation process for choosing which new medicines should be publically funded. This involved working closely with the Pharmac contract negotiators to establish innovative methods to get the most value from the NZ pharmaceutical budget.

Hayden now works at York Health Economics Consortium as a senior research consultant. He works on a range of projects from individual pharmaceuticals to wider public health initiatives including work for the NHS and Public Health England.

Hayden has previous experience in the Royal New Zealand Air Force, where he was an NCO in logistics where his experiences included peace keeping in Bougainville Island and re-supply missions to Antarctica. He is also a keen trail runner and is currently training for the 110km Hadrian's Wall ultramarathon in the UK.

ROBERTA JOPPI



CLINICAL PHARMACIST, ULSS 9 SCALIGERA

Roberta Joppi is a Clinical Pharmacist. She got her Chem Pharm degree, the specialisation in Clinical Pharmacy and a Master in Systematic Reviews at the Milan University. She worked at the Pharmacy Department of the following Hospitals: Regional Hospital in Bolzano, Regional Hospital in Rovigo, University Hospital in Verona. At present she is Head of the Clinical Research & Drug Assessment Unit – Pharma Department of the Local Health Authority in Verona and visiting Scientist at the Laboratory of Drug Regulatory Policies of the 'Mario Negri' Institute in Milan. She is responsible for the Italian Horizon Scanning Project, chair of the EuroScan International Network and member of the Piperska Group.

She was also member of the Steering Group of the WP8 on Development of a risk-adapted monitoring toolbox of the EU-ECRIN project. Her main areas of interest have been drug assessment, epidemiology of interventions, clinical trials and drug utilisation studies in the cardiovascular and psychiatric areas.

ELENA PAOLA LANATI



MANAGING DIRECTOR,
MA PROVIDER

Paola has worked for years as a manager in pharmaceutical companies (AstraZeneca, BMS, UCB, P&G), occupying the position of Business Unit Director, first in Primary Care and then in Specialty Care. In her carrier, she managed issues of market access (IPP, oncology, CNS) and dossiers of price negotiation. In 2010 she founded first 3P Solution and then MA Provider for which she won a selection in Lombardia Region for the launch of new companies, thanks to a project on the pricing of new drugs.

Businesswoman and Mom, Paola runs a growing team of 30 people, is passionate about pricing and patient advocacy, and loves to make her own contribution and to stimulate the challenges of our healthcare system. Founder and secretary of Ispor Italy Rome Chapter.

MARIO MELAZZINI

GENERAL DIRECTOR, AIFA

Mario Melazzini, medical doctor, specialized in general hematology and clinical laboratory, and researcher in the field of hematology-oncology, is currently Chairman of the Board of the Italian Medicines Agency (AIFA).

He was previously Director of the Oncology DH of the Scientific Institute for Research, Hospitalization and Healthcare "Fondazione Salvatore Maugeri" in Pavia.

He was also contract professor at the University of Pavia - Faculty of Medicine and Surgery.

He was Director of the complex structure of continuity of care hospital-territory of the Niguarda Ca 'Granda hospital in Milan and Director of Health Planning and Development of Lombardy Regional Plans.

He has covered the role of Councillor for Health, Councillor for Industry, Research and Innovation, and Councillor for Universities, Research and Open Innovation of the Lombardy Region.

He is member of the Technical Health Committee of the Ministry of Health and Chairman of the Commission for Health Research of the Ministry of Health (Section C).

He is the President of Aurora Onlus Foundation, belonging to the "Nemo Sud" Clinical Centre at the Azienda Ospedaliera Universitaria Policlinico 'G. Martino' in Messina and Scientific Director of the Clinical Center of Serena NeMo Onlus Foundation at the Niguarda Hospital in Milan.

He was Chairman of the Ministerial Commission on Neuromuscular Diseases at the Ministry of Health, where he was responsible for organizing and coordinating activities, and Member of the Working Group on Rehabilitation, in charge of updating the guidelines for rehabilitation activities, in cooperation with Italian Regional Authorities.


He was the Scientific Coordinator and Head of the Technical Discussion Group for Policies for People with Disabilities of the Lombardy Region.

He was the National President of both AISLA Onlus (Italian Association for Amyotrophic Lateral Sclerosis) and AriSLA Italian Foundation for research on Amyotrophic Lateral Sclerosis.

He was also National Secretary of the Italian Federation for the Overcoming of Handicaps (FISH).

He has published numerous scientific articles and he is author of several books related to his experience both as a doctor and as a patient.

ANNARITA MENEGUZ



BIOTECHNOLOGICAL MANAGER,
NATIONAL CENTER OF DRUG RESEARCH AND EVALUATION,
ISTITUTO SUPERIORE DI SANITÀ

Graduated in Biological Sciences at La Sapienza University in Rome. She is currently biotechnological manager at the Pharmaceutical Department of Istituto Superiore di Sanità, Director of the Department of pre-clinical pharmaceutical evaluation and Secretary of the Panel for the evaluation of admissibility to phase I clinical experimentation. In the field of research, she is interested in pharmacokinetics and neurotoxicity of xenobiotics.

She is Regulatory Assessor as part of the clinical evaluation (IV form of the CTD) of drugs for human use, subject of the centralized registration procedure of the European Medicines Agency (EMA) and the non-clinical evaluation of drugs under investigation. She is the Italian member of the Safety Working Party of EMA, HLP Inspector Coordinator and Italian member of OECD GLP Working Group.

CINZIA MORTARINO



ASSOCIATE PROFESSOR, DEPARTMENT OF STATISTICAL SCIENCES,
PADUA UNIVERSITY

Born in 1969, she received her Ph.D. degree in Applied Statistics to Economic and Social Sciences from the University of Padua and worked as an Assistant Professor also in the Faculty of Economics at the University of Modena and Reggio Emilia, Italy. Her research interests include design of experiments, statistical quality control, innovation diffusion models, statistical methodology and applications. In detail, recently she focused on models for the diffusion of photovoltaic energy and analysis of incentive policies, models for the description of competition among brands within a common market, and inferential procedures for nonlinear models. A specific attention has been paid in the last years to the study of the lifecycle of pharmaceutical drugs both from a univariate point of view and with reference to their competition within the pharmaceutical market.

CAROLE OMNÈS



VICE PRESIDENT MARKET ACCESS, CEMKA EVAL

Carole Omnès is VP Head of Market Access for drugs throughout their lifecycle, from strategic pricing and reimbursement advices and evidence-based value messages to dossiers preparation, writing and follow-up with stakeholders. Business oriented, Carole's multidisciplinary team is dedicated to qualitative outcomes to satisfy both company and health authorities needs. Before joining Cemka-Eval, Carole gained over 12 years experience within the pharmaceutical industry leading market access and health economics positions, both at French and Corporate levels, where she contributed in obtaining successful pricing and reimbursement conditions for various products franchises (oncology, haematology, immunology, rheumatology, allergy, anemia, transplants, virology, vaccines).

Carole is a Pharmacist Doctor (PharmD University of Paris XI Chatenay-Malabry) and holds a master's degree in health economics (University Paris Dauphine).

She is a member since 2003 of the CES (French College of Health Economists) and ISPOR (International Society for Pharmacoeconomics and Outcomes Research). She is a co-author in health economics published studies (oncology – Coudray-Omnès) and also does lectures at university level (University Paris XI Chatenay Malabry Master Health Economics and Market Access, University Paul Sabatier of Toulouse).

RICCARDO PALMISANO



PRESIDENT, ASSOBIOTEC

Riccardo Palmisano, CEO at MolMed, graduated in Medicine at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986). In 1988, he moved on to Menarini Group where contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy (1993) and General Manager at Lusofarmaco (1995). His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi, he was appointed Director of Business Strategy and Development at Sanofi Italia too (2012-2013). Between 2014 and 2015, before moving to MolMed, Palmisano was Genzyme not operating Chairman, President of Siena Biotech, as well as member of the Steering Committee of Rare Partners and consultant for some innovative start-ups in the life sciences area. In 2008, he joined Assobiotech, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, he was appointed President of Assobiotech.

FRANCESCA PATARNELLO



VICE PRESIDENT MARKET ACCESS & GOVERNMENT AFFAIRS,
ASTRAZENECA ITALIA

Francesca Patarnello is, since March 2017, Vice President Market Access & Government Affairs, AstraZeneca Italia. Degree in Statistics and Economics, she began her career at Farmitalia Carlo Erba, passing successively from Fidia to GlaxoSmithKline. Before AstraZeneca she spent three years as Value and Access Director in Amgen, working to make accessible to patients the innovative pipeline. Before moving to the Market Access, she plays a number of roles in medical science, including HTA Director and Scientific Director and Quality.

Member of several working groups, Francesca currently sits on the Board of Directors of SIHTA (Society of Health Technology Assessment) and also held a series of academics positions at the University of Bologna, Catania, Novara, Padova and Verona. She is co-author of numerous publications regarding innovation of drugs, on HTA and on market access.

MASSIMO PIERMATTEI



MEMBER OF THE DIRECTORATE OF FIMIV – ITALIAN FEDERATION OF INTEGRATIVE
VOLUNTARY MUTUALITY, AND OF AIM - INTERNATIONAL ASSOCIATION OF
MUTUAL BENEFIT SOCIETES, REPRESENTING FIMIV

Massimo Piermattei graduated in Law and after the degree he achieved professional experiences as attorney-at-law in several law firms and as a publicist in collaboration with journals. Since 1993, he is General Manager of CAMPA, one of the most important mutual societies of complementary healthcare in Italy. In this role, he achieved experience in the management and design of complementary health coverage for NHS with voluntary participation and of healthcare funds addressed to employees. Since 1994, he is member of the national board of FIMIV (Italian Federation of Integrative Voluntary Mutuality) and spokesman of the Coordination FIMIV Emilia Romagna, of which he is President since 2009. Since 2006, he is counselor of the consortium of mutual health organizations (Mu.Sa.) and general coordinator of the network of healthcare facilities. Currently, he is Vice-President of Mu.Sa. consortium. Since 2010, he is member of the board of Federazione Sanità Emilia Romagna. Since 2015, he is one of the representing members of FIMIV at AIM – International Association of Mutual Benefit Societies.

PATRIZIA POPOLI



HEAD, NATIONAL CENTER OF DRUG RESEARCH AND EVALUATION,
ISTITUTO SUPERIORE DI SANITÀ

Patrizia Popoli obtained a degree in Medicine and Surgery at the Università degli Studi in Perugia. She majored in neurological clinic at the Università degli Studi in Perugia. Currently, she is leader of research at the Department of Pharmacology at Istituto Superiore di Sanità, Director of the unit of Central Nervous System Pharmacology and member of the Committee for the evaluation of admission to Phase I clinical trials.

She has been for many years permanent substitute of the President of Istituto Superiore di Sanità in the Scientific and Technical Committee of AIFA and is currently President of this Committee. In the field of research, Patrizia is interested in Central Nervous System Pharmacology.

She is a member of national and international scientific societies and author of several publications. Furthermore, she performs numerous regulatory activities in the pharmaceutical sector.

ORIOLO SOLÀ-MORALES



CEO, HEALTH INNOVATION TECHNOLOGY TRANSFER

Oriol Solà-Morales is the CEO-Director of the "Institut d'Investigació Sanitària Pere Virgili", Barcelona.

Oriol de Solà-Morales (MD, PhD) is a clinician specialised in Internal Medicine, with a Master of Science in Health Policy, Planning and Financing, from the London School of Economics and Political Science (LSE).

He has worked as Coordinator of the Health Policy Unit of the Agencia de Evaluación de Tecnología e Investigación Médicas (AATRM) and as Health Coordinator at the la Orden Hospitalaria San Juan de Dios – Aragón.

After being Director of the AATRM, he has also worked as Medical and Market Access Director at Sabirmedical.

GIUSEPPE TOFFOLI



DIRECTOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY UNIT CRO-
NATIONAL CANCER INSTITUTE

Dr. Toffoli is the director of the Clinic and Experimental Pharmacology Unit at the National Cancer Institute (CRO) of Aviano, Italy. He holds a MS Degree in Medicine from the University of Padova, Italy, with a specialty in Oncology and Clinical Pharmacology. He is Visiting Professor of Nanotechnology at the Doctoral School in Nanotechnology University of Trieste, Italy and Visiting Professor of Pharmacology at the Doctoral School of Pharmacological Science of the University of Padova, Italy. He was also Visiting Professor of Oncology Pharmacology at the University of Trieste, Italy. Dr. Toffoli has been actively involved in several Italian and international scientific associations, and he has served in a number of National Ethical Committees including Burlo Garofalo, Trieste; CRO, Aviano; Pordenone Hospital, Pordenone and in the Directing Committee of the University and Hospital Health of Udine. At present, he is member of the Technical Scientific Committee of the Italian Medicines Agency (AIFA). He has published over 200 articles in reputed international journals, serving on the Editorial Board of many international scientific journals. Dr Toffoli has also overseen and directed many projects sponsored by both Italian and European research institutions and NGOs, including AIRC 5 per Mille Special Program and Horizon 2020. Dr. Toffoli is a highly qualified researcher in the field of Pre-Clinic and Clinic Pharmacology, Molecular and Biochemical Mechanisms and Genomics of Anti-Cancer Drugs. His research team has gained direct experience in the field of "traslational research" and regulatory procedures by conducting Phase I and Phase II Clinic Trials. His research has been recently focused on Nanomedicine issues, with the aim of developing both innovative diagnostic tools for therapeutic drug monitoring and circulating plasma biomarkers.

GIACOMINO VALLAR



RESPONSIBLE FOR NETWORKS AND AGREEMENTS,
UNISALUTE S.P.A

Giacomino Vallar – specialised in Cardiology and graduated in Medicine at the University of Bologna. From 1990 to 2005 he worked as medical examiner for some primary companies. Since October 1995, he has been responsible for the healthcare service of the insurance company UniSalute S.p.A. In this field, he managed medical controversies, he drafted the liquidation philosophy, and worked as technical support for complex claims, as a support for assistance, management and supervision of sanitary repatriation. Furthermore, he dedicated himself to technical support in the commercial area both in the construction of products and in the customers management. In the start-up phase of the company, he participated to the construction of healthcare networks. He is responsible for the construction of the management model, of the agreement model and of the management of dentist network. Since 1997, he has been managing other activities like medical support in the Ramo Vita area and damages for Unipol group. Since February 2006, he has been responsible for networks and agreements of UniSalute. Since October 2008, he has been responsible for the coordination of physicians of Unipol group. Since 2016, he has been responsible for the medical centres of UniSalute.

Thursday, 4th May 2017 | h. 14.00-18.30

Friday, 5th May 2017 | h. 09.00 - 14.00

Palazzo Giureconsulti

Piazza Mercanti 2 - 20123 Milano Italia

Tel +39 02 85155873 | Fax: +39 02 85155857

BY TRAIN

From Centrale Station, take the underground MM3 (yellow line) and get off at Duomo.

BY PLANE

From Linate Airport, take the line 73 (Aeroporto - Duomo M1 M3). Get off at stop C.so P.ta Vittoria and take the line 19 (Lambrate M2 station- Roserio). Get off at stop Via Orefici / P.za Cordusio.

MEMBERSHIP

Registration fee 1.200,00 € + VAT

To participate you must register at the Organizing Secretariat, by returning the completed registration form (downloadable by the specific link in the menu on left) and making the payment of the amount, in the manner specified on the same.

The registration fee includes:

- participation in the works
- congress kit
- certificate of participation
- lunch, coffee break



MARKET ACCESS AWARD 2017

The Market Access Award 2017, at its third edition, wants to reward the best partnership between private companies and public institutions aimed to optimize the patient care access through innovative solutions.

The evaluation criteria to assign the prize will be:

- ✓ scientific value of the project
- ✓ benefit to patients
- ✓ innovation and added value in the interaction between private and public
- ✓ replicability of the project

The judging board will be composed by:

- **Pier Luigi Canonico**
Director of the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale
- **Antonio Gaudio**
Secretary-General of CittadinanzAttiva
- **Armando Genazzani**
Full Professor of Pharmacology, Università degli Studi del Piemonte Orientale
- **Claudio Jommi**
Associate Professor at the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale; Scientific Director Drugs Observatory, Cergas, Università Bocconi; President of the Italian Association of Health Economics
- **Elena Paola Lanati**
Managing Director, MA Provider, Milan
- **Franco Perrone**
Director Clinical Trials Unit National Cancer Institute of Naples
- **Walter Ricciardi**
President of the National Institute of Health, Rome
- **Alessandro Sorrone**
Secretariat to the Governing Body HTA, Ministry of Health, Rome



NOTES

MILAN, MAY 4th | 5th, 2017



via Carducci 24
20123 Milano
tel +39 02 89096682
fax +39 02 89098927
e-mail | info@maprovider.com

piazza San Salvatore in Lauro 10
00186 Roma
tel | fax +39 06 68806614
e-mail | info.roma@maprovider.com

web | www.maprovider.com

